Overview Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer Status: Completed Trial end date: 2009-01-01 Target enrollment: Participant gender: Summary The purpose of this study is to learn whether HKI-272 is safe and effective in treating non-small cell lung cancer. Phase: Phase 2 Details Lead Sponsor: Puma Biotechnology, Inc.